Data from Pharmawand - Curated by EPG Health - Date added 13 February 2019

Bristol-Myers Squibb Company announced new results from the Phase III CheckMate -214 study, showing that therapy with Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) continued to demonstrate long-term survival benefits in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC).

With a minimum follow-up of 30 months, intermediate- and poor-risk patients randomized to Opdivo plus low-dose Yervoy continued to show a significant overall survival (OS) benefit compared to those randomized to sunitinib. Additionally, at 30 months, the objective response rate (ORR) per investigator for intermediate- and poor-risk patients with Opdivo plus low-dose Yervoy improved compared to the previous analysis at a minimum of 17.5 months.OS: The 30-month OS rate for the intermediate- and poor-risk population was 60% for patients treated with Opdivo plus low-dose Yervoy versus 47% for patients treated with sunitinib [Hazard Ratio (HR) 0.66 (95% Confidence Interval [CI]: 0.54, 0.80); p<0.0001]. ORR: Opdivo plus low-dose Yervoy was associated with a 42% ORR versus 29% with sunitinib (p=0.0001). More than half (52%) of the intermediate- and poor-risk patients who responded to Opdivo plus low-dose Yervoy had a response lasting at least 18 months versus 28% of the patients who responded to sunitinib. Complete Response (CR): The CR rate was 11% with Opdivo plus low-dose Yervoy versus 1% with sunitinib.

The results were similar for the intention -to-treat (ITT, i.e., all randomized) population with Opdivo plus low-dose Yervoy, demonstrating significantly improved:OS: The 30-month OS rate for the ITT population was 64% for patients treated with Opdivo plus low-dose Yervoy versus 56% for patients treated with sunitinib [HR 0.71 (95% CI: 0.59, 0.86); p=0.0003]. ORR: The ORR was 41% with Opdivo plus low-dose Yervoy versus 34% for sunitinib (p=0.015).CR: The CR rate was 11% with Opdivo plus low-dose Yervoy versus 2% with sunitinib. The overall safety of the combination was consistent with that observed in the 17.5-month minimum follow-up analysis and with previously reported studies of these medicines in patients with RCC. No new safety signals or drug-related deaths occurred with extended follow-up.

The data will be featured in a rapid oral presentation (Abstract #547) on Saturday, February 16, 2019 at the American Society of Clinical Oncology 2019 Genitourinary Cancers Symposium in San Francisco..

Comments

You will need to login, to leave a comment.

epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Biosimilars Knowledge Centre

Biosimilars Knowledge Centre

What are biologics and how do they differ from small molecule medicines? Discover more about their development, as well as the manufacturing and regulatory processes in the Biosimilars in Oncology Knowledge Centre.

CDK 4/6 inhibitors in metastatic breast cancer

CDK 4/6 inhibitors in metastatic breast cancer

The CDK 4/6 Inhibitors in Metastatic Breast Cancer Learning Zone provides insights and information for metastatic breast cancer (mBC) and CDK 4/6 signalling. This includes the burden and pathophysiology of the disease, the role of CDK 4/6 in cell proliferation and an overview of the CDK 4/6 inhibitors that have been approved for the management of mBC.

Load more

Related Content